Henry Gosebruch was appointed Director of Ani Pharmaceuticals Inc. As of November 6, 2026, Ani Pharmaceuticals Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 24, 2026, naming 1 appointment (Form 8-K, August 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ani Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Ani Pharmaceuticals Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-24. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Ani Pharmaceuticals Inc files it.
Also on the record for Ani Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 12.8% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Millennium Management LLC | 0.3% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 11.3% of the class | 5%+ stakes | Source |
| August 22, 2025 | Stake report, Schedule 13D/A, by Meridian Venture Partners II GP, L.P. ("GP") | 4.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Ani Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Ani Pharmaceuticals Inc and the records around it.
Ani Pharmaceuticals Inc elsewhere on the record
Companies that share a holder
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Ani Pharmaceuticals Inc
Get an email when Ani Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ani Pharmaceuticals Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ani Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ani Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-24 | In | Director | 8-K, 2026-08-24 |
Who leads Ani Pharmaceuticals Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Henry Gosebruch, appointed (filed 2026-08-24).
New leaders reset buying decisions — get the Full Report on Ani Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Ani Pharmaceuticals Inc, with the record behind each one.
Find candidates like Director at Ani Pharmaceuticals IncEvery change, in the filing's words
Appointed: Henry Gosebruch, Director
On August 19, 2026, the Board of Directors (the "Board") of ANI Pharmaceuticals, Inc. (the "Company") appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company's 2027 annual meeting of stockholders.
- Mr. Gosebruch, 53, has served as Chief Executive Officer and a member of the board of directors of Lakefront Biotherapeutics NV, a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need, since May 2025.
- Prior to Lakefront, Mr. Gosebruch served as President and Chief Executive Officer of Neumora Therapeutics, Inc., a publicly traded neuroscience company, from July 2023 to February 2025.
- Prior to Neumora, he was Executive Vice President and Chief Strategy Officer at AbbVie Inc. from December 2015 to February 2023, where his responsibilities included corporate strategy, competitive intelligence, business development, and M&A. Prior to joining Abbvie in 2015, Mr. Gosebruch spent over 20 years at J.P. Morgan, where he was Co-Head of the North American M&A Group.
- As a non-employee director, Mr. Gosebruch is eligible to participate in the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (the "Plan").
Tools for this story
Each opens in a new tab, filled in for Ani Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.